TWI649082B - 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法 - Google Patents

使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法 Download PDF

Info

Publication number
TWI649082B
TWI649082B TW102109912A TW102109912A TWI649082B TW I649082 B TWI649082 B TW I649082B TW 102109912 A TW102109912 A TW 102109912A TW 102109912 A TW102109912 A TW 102109912A TW I649082 B TWI649082 B TW I649082B
Authority
TW
Taiwan
Prior art keywords
cancer
onora
kinase
paclitaxel
cell
Prior art date
Application number
TW102109912A
Other languages
English (en)
Chinese (zh)
Other versions
TW201343169A (zh
Inventor
亞里吉特 查卡瓦堤
Arijit CHAKRAVARTY
傑佛瑞Ａ 艾克塞迪
Jeffrey A. Ecsedy
羅伯特Ｗ 克林佛德
Robert W. Kleinfield
哈Ｎ 李
Kha N. Le
徐文起
Wen Chyi Shyu
卡席克 凡卡達克里斯漢
Karthik VENKATAKRISHNAN
Original Assignee
美商千禧製藥公司
Millennium Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商千禧製藥公司, Millennium Pharmaceuticals, Inc. filed Critical 美商千禧製藥公司
Publication of TW201343169A publication Critical patent/TW201343169A/zh
Application granted granted Critical
Publication of TWI649082B publication Critical patent/TWI649082B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW102109912A 2012-03-20 2013-03-20 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法 TWI649082B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613258P 2012-03-20 2012-03-20
US61/613,258 2012-03-20

Publications (2)

Publication Number Publication Date
TW201343169A TW201343169A (zh) 2013-11-01
TWI649082B true TWI649082B (zh) 2019-02-01

Family

ID=48048255

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102109912A TWI649082B (zh) 2012-03-20 2013-03-20 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法

Country Status (24)

Country Link
US (2) US20130303519A1 (enExample)
EP (1) EP2827855B1 (enExample)
JP (1) JP6373252B2 (enExample)
KR (1) KR102128866B1 (enExample)
CN (1) CN104271129A (enExample)
AU (1) AU2013235275B2 (enExample)
CA (1) CA2868024A1 (enExample)
EA (1) EA036434B1 (enExample)
ES (1) ES2746946T3 (enExample)
GE (2) GEAP201813599A (enExample)
IL (1) IL234686B (enExample)
IN (1) IN2014DN08477A (enExample)
JO (1) JO3630B1 (enExample)
MA (1) MA37438A1 (enExample)
MX (1) MX358411B (enExample)
MY (1) MY175225A (enExample)
NZ (1) NZ700744A (enExample)
PH (1) PH12014502109A1 (enExample)
SG (2) SG11201405621UA (enExample)
TN (1) TN2014000387A1 (enExample)
TW (1) TWI649082B (enExample)
UA (1) UA117455C2 (enExample)
WO (1) WO2013142491A1 (enExample)
ZA (1) ZA201407551B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
EP3236948A4 (en) * 2014-12-23 2018-10-03 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
US20190194750A1 (en) * 2015-07-02 2019-06-27 Millennium Pharmaceuticals, Inc. Biomarkers of response to selective inhibitors of aurora a kinase
CN110833544B (zh) * 2018-08-17 2022-08-09 深圳微芯生物科技股份有限公司 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
SU1181547A3 (ru) 1979-02-07 1985-09-23 Ф.Хоффманн-Ля Рош Унд Ко,Аг (Фирма) Способ получени пиримидо-2-бензазепинов или их фармакологически совместимых кислотно-аддитивных солей (и его вариант)
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0888350A1 (en) 1996-03-08 1999-01-07 Zeneca Limited Azolobenzazepine derivatives as neurologically active agents
AU5330698A (en) 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
DK1026167T3 (da) 1997-09-29 2003-05-26 Meiji Seika Kaisha Tricykliske triazolobenzazepinderivater, fremgangsmåde til fremstilling af disse samt antiallergiske midler
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
HUP0401107A3 (en) 2001-08-09 2004-10-28 Actelion Pharmaceuticals Ltd Novel benzo-fused heterocycles, their use process for their preparation and pharmaceutical compositions containing them
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
EP1718303A4 (en) 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
KR101792651B1 (ko) 2004-05-14 2017-11-20 밀레니엄 파머슈티컬스 인코퍼레이티드 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물
MX2007005857A (es) 2004-11-17 2007-10-10 Mikana Therapeutics Inc Inhibidores de cinasa.
EP1836188A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
WO2007076348A2 (en) 2005-12-23 2007-07-05 Smithkline Beecham Corporation Azaindole inhibitors of aurora kinases
BRPI0621024A2 (pt) 2006-01-16 2011-11-29 Jubilant Organosys Ltd formulação farmacêutica estável de um composto de ácido lábil e o processo para preparação do mesmo
AR059838A1 (es) 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
DE102006012301A1 (de) 2006-03-15 2007-09-20 Cemag-Anlagenbau-Dessau Gmbh Herstellung von Zementklinker
WO2008021038A2 (en) 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
EP2077850A2 (en) 2006-10-31 2009-07-15 Achillion Pharmaceuticals, Inc. Elvucitabine pharmaceutical compositions
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
MX2010013562A (es) 2008-06-26 2011-02-15 Anterios Inc Aplicacion dermica.
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
WO2011103089A1 (en) * 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies",http://clinicaltrials.gov/archive/NCT01045421/2012_01_30, 網路公開日期：2012年1月30日.
"Randomized Phase 2 Study of , an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer,"http://clinicaltrials.gov/archive/_06, 網路公開日期：2011年12月6日. E. C. Dees,et al."Phase I study of the investigational drug , an Aurora A kinase (AAK) inhibitor, in patients (pts) with solid tumors",Journal of Clinical Oncology 28, no. 15_suppl (May 2010) 3010-Abstract. TF Wang,et al."A Phase II Study of Weekly Paclitaxel and Epirubicin in Recurrent or Refractory Squamous Cell Carcinoma of the Head and Neck",Jpn J Clin Oncol 2008;38(7)459~463. "A Phase 1 Dose Escalation Study of , an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies",http://clinicaltrials.gov/archive/_30, 網路公開日期：2012年1月30日. N YAMAMOTO *
"Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer,"http://clinicaltrials.gov/archive/NCT01091428/2011_12_06, 網路公開日期：2011年12月6日.
E. C. Dees,et al."Phase I study of the investigational drug MLN8237, an Aurora A kinase (AAK) inhibitor, in patients (pts) with solid tumors",Journal of Clinical Oncology 28, no. 15_suppl (May 2010) 3010-Abstract.
N YAMAMOTO,et al."Phase II Study of Weekly Paclitaxel for Relapsed and Refractory Small Cell Lung Cancer",ANTICANCER RESEARCH 26: 777-782 (2006).
TF Wang,et al."A Phase II Study of Weekly Paclitaxel and Epirubicin in Recurrent or Refractory Squamous Cell Carcinoma of the Head and Neck",Jpn J Clin Oncol 2008;38(7)459~463.

Also Published As

Publication number Publication date
WO2013142491A1 (en) 2013-09-26
PH12014502109A1 (en) 2014-12-10
MX2014011324A (es) 2014-12-05
US20160193224A1 (en) 2016-07-07
EP2827855A1 (en) 2015-01-28
KR102128866B1 (ko) 2020-07-01
UA117455C2 (uk) 2018-08-10
EP2827855B1 (en) 2019-06-26
EA201491727A1 (ru) 2015-01-30
TN2014000387A1 (en) 2015-12-21
ES2746946T3 (es) 2020-03-09
IL234686B (en) 2020-01-30
SG10201607741RA (en) 2016-11-29
HK1206253A1 (en) 2016-01-08
MY175225A (en) 2020-06-16
US20130303519A1 (en) 2013-11-14
GEAP201813599A (en) 2018-06-25
CA2868024A1 (en) 2013-09-26
JP2015510945A (ja) 2015-04-13
US10213436B2 (en) 2019-02-26
KR20140144215A (ko) 2014-12-18
TW201343169A (zh) 2013-11-01
JP6373252B2 (ja) 2018-08-15
SG11201405621UA (en) 2014-10-30
ZA201407551B (en) 2019-01-30
MX358411B (es) 2018-08-20
GEP20186900B (en) 2018-10-10
MA37438A1 (fr) 2016-05-31
NZ700744A (en) 2016-09-30
IL234686A0 (en) 2014-11-30
AU2013235275A1 (en) 2014-10-23
CN104271129A (zh) 2015-01-07
IN2014DN08477A (enExample) 2015-05-08
EA036434B1 (ru) 2020-11-10
AU2013235275B2 (en) 2017-12-07
JO3630B1 (ar) 2020-08-27

Similar Documents

Publication Publication Date Title
CN114761012B (zh) 组合疗法
US20240189300A1 (en) Therapeutic agent for solid cancers, which comprises axl inhibitor as active ingredient
RS66424B1 (sr) Kombinovane terapije
CN103957709A (zh) Mek抑制剂与奥诺拉(aurora)a激酶选择性抑制剂的组合
JP2017533223A (ja) ユビキチン活性化酵素阻害物質及び化学療法剤の投与
JP2016539156A (ja) オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
EP2512469A1 (en) 3-(indolyl)-or 3-(azaindolyl)- 4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarzinoma
JP7179174B2 (ja) スルホンアミド化合物と免疫調節剤を用いるがん併用療法
JP2018514557A (ja) Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法
Li et al. Discovery of the first BRD4 second bromodomain (BD2)-selective inhibitors
US20230019999A1 (en) Combination drug
WO2014177915A1 (en) Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
JP2025519119A (ja) Ｍｅｋ阻害剤及びその使用
WO2024173761A1 (en) Combinations comprising mek inhibitors for use in the treatment of cancer
JP6373252B2 (ja) オーロラキナーゼ阻害薬を使用する癌の治療方法
AU2014280354A1 (en) Combinations for the treatment of cancer comprising a Mps-1 kinase inhibitor and a mitotic inhibitor
WO2020142745A1 (en) Methods of treating graft versus host disease and neoplastic disease with amide compounds
JP6073480B2 (ja) ＰＩ３Ｋおよび／またはｍＴＯＲ阻害剤
CN117377471A (zh) 治疗肿瘤的联合疗法
HK1206253B (en) Combination of alisertib and paclitaxel for the treatment of cancer
HK40074319A (en) Combination therapies